Jubilant Life Sciences’ Exclusive Synthesis business acts as an outsourcing partner for many Life Science innovators and has adopted 'Active Selection' concept for the wide range of services it offers to its customers.

Given the challenges faced by the Pharma industry today "Survival of the Fittest" becomes imperative necessitating active adaptation to the new environment. It is therefore refreshing to discuss your challenges with a service provider who can implement flexible & scalable solutions in a confidential and secure framework; a symbiotic collaboration, aimed at helping you enhance your success. We offer complete Drug Life Cycle Services for Global Pharma. Active Selection for Success The Life cycle graph below gives a typical drug development life span and suggests schematically where Jubilant Exclusive Synthesis and Active Selection might be considered. Jubilant is happy to share its skills and co-partner with other successful innovators.

We offer complete Drug Life Cycle Services for Global Pharma.

Active Selection for Success
The Life cycle graph below gives a typical drug development life span and suggests schematically where Jubilant Exclusive Synthesis and Active Selection might be considered.

Jubilant is happy to share its skills and co-partner with other successful innovators.

Focus On Excellence in R & D

R & D Services
Jubilant provides Process R & D, Scale-Up and Manufacturing Services to Pharma and Life Sciences Innovators for Intermediates, both cGMP and non-GMP and APIs as well as Dosage Forms.

• Route design, process development and process optimization from phase I to III.
• Process improvement for launched products, dosage as well as actives.
• Regulatory and Analytical support required for CMC section of registrations.

These processes are developed with criteria on environmental impact, scalability, ease of operation and robustness. Jubilant applies Design For Six Sigma (DFSS) and Design of Experiments (DOE) concepts to develop these processes.

R & D Facilities

• Exclusive Synthesis has R&D facilities at Noida and Gajraula (near Delhi) for Intermediates, APIs and solid dosage forms.
• Fully Equipped analytical laboratory with advance equipment including:
  • NMR, XRD, Reaction Calorimeter, LC-MS, Prep HPLC, Particle size analyzer, Optical microscope, Stability Chambers, Polarimeter, IR, DSC,TSC etc.
  • All projects in R&D are properly coded and distributed to maintain strict confidentiality.

Exclusive Synthesis-Intermediates & APIs

Custom Manufacturing Intermediates & APIs
Jubilant focuses on manufacturing of both Clinical and Commercial phase products from grams to kilo’s and 100’s of tons.

Supply of Generic APIs:
Jubilant produces a range of APIs based on its leading Pyridine position, manufactured at its US FDA approved API facility at Nanjangud in India. We are able to tailor the product to fit your requirements be it for combination products or branded generics.

Manufacturing Facilities
Active Selection demands continuous improvement of facilities with heavy investment.

cGMP Pilot Plants
We have state-of-art Kilo-Lab and Pilot plants both at Gajraula (Near Delhi) for Non-Regulatory steps synthesis and at Nanjangud (Near Bengaluru) for Regulatory steps.

• Reactors ranging from 20L to 630L (Including Glass assemblies and Cryogenic reactors, Autoclaves operating at 58 Kg/cm2 and 280^oC)
• Operations at both very high (450oC) and very low (-80^oC) temperatures.

Commercial Plants
Jubilant operates large commercial plants at Gajraula (Near Delhi) for Non-Regulatory steps and at Nanjangud (Near Bengaluru) for cGMP intermediates and APIs. The Nanjangud facility is USFDA approved.

• Nanjangud has 107 reactors (Including Hastelloy and Cryogenic) ranging from 1 KL to 12 KL with a reactor volume of 650 KL along with Autoclaves operating at 58 kg/cm² & 280^oC, Bromination and Fluorination facilities.
• Gajraula has 100 reactors (Including MSGLR, SS, Hastealloy and Cryogenic) ranging from (1KL to 12 KL) with a reactor volume of 600 KL, along with Autoclaves operating at 58 Kg/cm² & 280^oC, Bromination and Fluorination facilities
• High Vacuum System, Highly Efficient Distillation Columns with structured packing of 30 meters packed height, Solvent Recovery Plants.
• DCS process control systems used widely.

Your Active Selection & Exclusive Synthesis

• We work with large & mid-size Innovator Pharma, Biotech & Crop Science Companies.
• Jubilant supplies commercial products and executed several long-term agreements.
• Several commercial scale projects are in late phase discussions.
• Several projects are in progress in Phase-I, Phase-II and Phase III.

Technology Platforms

All core technologies and chemical conversions are operated at large scale and are globally competitive. Jubilant has a long track record in safely operating a range of hazardous processes.

The classical chemical technologies are also operated at various scales of manufacturing. For more detailed questions please contact your BD representative.

Jubilant emerged as the global leader for pyridine & piperidines and their derivatives and through backward integration and continuous technology finetuning has achieved a sustainable and competitive supply position for the future. Project Management

Every customer project is handled with care by a certified Project Manager to ensure:

• Single Point of Contact for customers who coordinates internally with various functions.
• Communicates regularly with customers on project progress, documentation etc.
• Tracks progress in every stage using Enterprise Project Management (EPM) software.
• A project management office (PMO) has been set up to further improve overall coordination.

Jubilant Exclusive Synthesis - Your Partner of Choice

The Customer sits at the focus of Jubilant 'Active Selection'

• Lean 6 Sigma, Modern Production facilities and international best practice are cornerstones of the Exclusive Synthesis business model.
• Positive Evolution of cost effective drug production and delivery to patients is a demand led worldwide reality.
• Enhanced Competition means that growth in the future demands adaptation to this new environment.
• Active Selection from Jubilant Exclusive Synthesis supports our partners so they in turn can fully focus on servicing patients globally in a changing pharma world.